Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ANTIBODY THERAPY

One hits (almost) all

Therapeutic efficacy in inflammatory diseases is hampered by disease complexity. A monoclonal antibody that neutralizes IL-1R3, the common co-receptor of most inflammatory IL-1 cytokines, opens up new perspectives in effective disease management.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Multiple IL-1 cytokines involved in inflammatory diseases act through IL-1R3.

References

  1. Højen, J. et al. Nat. Immunol. https://doi.org/10.1038/s41590-019-XXXX (2019).

  2. Philippidis, A. Genetic Engineering and Biotechnology News: GEN https://www.genengnews.com/a-lists/top-15-best-selling-drugs-of-2018/ (2019).

  3. Schork, N. J. Nature 520, 609–611 (2015).

    Article  CAS  Google Scholar 

  4. Dinarello, C. A. Semin. Immunol. 25, 389–393 (2013).

    Article  CAS  Google Scholar 

  5. Rider, P., Carmi, Y., Voronov, E. & Apte, R. N. Semin. Immunol. 25, 430–438 (2013).

    Article  CAS  Google Scholar 

  6. Yasuda, K. et al. Int. J. Mol. Sci. 20, 649 (2019).

    Article  CAS  Google Scholar 

  7. Martin, N. T. & Martin, M. U. Nat. Immunol. 17, 122–131 (2016).

    Article  CAS  Google Scholar 

  8. Bassoy, E. Y., Towne, J. E. & Gabay, C. Immunol. Rev. 281, 169–178 (2018).

    Article  CAS  Google Scholar 

  9. Li, T. et al. Sci. Translat. Med. 11, eaan2585 (2019).

    Article  Google Scholar 

  10. Johnston, A. et al. J. Allergy Clin. Immunol. 140, 109–120 (2017).

    Article  CAS  Google Scholar 

  11. Borthwich, L. A. Semin. Immunopathol. 38, 517–534 (2016).

    Article  Google Scholar 

  12. Dinarello, C. A., Simon, A. & van der Meer, J. W. Nat. Rev. Drug Discov. 11, 633–652 (2012).

    Article  CAS  Google Scholar 

  13. Ridker, P. M. et al. N. Engl. J. Med. 377, 1119–1131 (2017).

    Article  CAS  Google Scholar 

  14. Ridker, P. M. et al. Lancet 390, 1833–1842 (2017).

    Article  CAS  Google Scholar 

  15. ClinicalTrials.gov (U.S. National Library of Medicine, 2019); https://clinicaltrials.gov/ct2/show/NCT01767857.

  16. ClinicalTrials.gov (U.S. National Library of Medicine, 2019); https://clinicaltrials.gov/ct2/show/NCT03496974.

  17. Boraschi, D., Italiani, P., Weil, S. & Martin, M. U. Immunol. Rev. 281, 197–232 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Diana Boraschi, Ron N. Apte or Michael U. Martin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boraschi, D., Apte, R.N. & Martin, M.U. One hits (almost) all. Nat Immunol 20, 1095–1097 (2019). https://doi.org/10.1038/s41590-019-0463-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-019-0463-5

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing